A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: Activation-dependent regulation of ERK by p85 in multiple myeloma cells

Human Molecular Genetics

Volumn 18, Issue 11, 2009, Pages 1951-1961

  Salazar, Lisa ^a   Kashiwada, Tamara ^a   Krejci, Pavel ^b,c,d   Muchowski, Paul ^e,f   Donoghue, Daniel ^g   Wilcox, William R ^b,h   Thompson, Leslie Michels ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c MASARYK UNIVERSITY   (Czech Republic)

^d INSTITUTE OF BIOPHYSICS   (Czech Republic)

^e GLADSTONE INSTITUTE OF NEUROLOGICAL DISEASE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE P85ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE P85BETA; PHOSPHOLIPASE C GAMMA; PHOSPHOTRANSFERASE; PROTEIN P50; PROTEIN P55; RAS PROTEIN; SMALL INTERFERING RNA; TYROSINE; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CANCER CELL CULTURE; CARCINOGENESIS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TWO HYBRID SYSTEM;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BINDING SITES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HELA CELLS; HUMANS; MULTIPLE MYELOMA; PROTEIN BINDING; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION;

MAMMALIA;

EID: 65549164714     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddp116     Document Type: Article

References (81)

1. Eswarakumar, V.P., Lax, I. and Schlessinger, J. (2005) Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev., 16, 139-149.
2. L'Hote, C.G. and Knowles, M.A. (2005) Cell responses to FGFR3 signalling: Growth, differentiation and apoptosis. Exp. Cell Res., 304, 417-431.
3. Thisse, B. and Thisse, C. (2005) Functions and regulations of fibroblast growth factor signaling during embryonic development. Dev. Biol., 287, 390-402.
4. Chaffer, C.L., Dopheide, B., Savagner, P., Thompson, E.W. and Williams, E.D. (2007) Aberrant fibroblast growth factor receptor signaling in bladder and other cancers. Differentiation, 75, 831-842.
5. Ornitz, D.M. and Marie, P.J. (2002) FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev., 16, 1446-1465.
6. Ronchetti, D., Greco, A., Compasso, S., Colombo, G., Dell'Era, P., Otsuki, T., Lombardi, L. and Neri, A. (2001) Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): Comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene, 20, 3553-3562.
7. Webster, M.K. and Donoghue, D.J. (1997) FGFR activation in skeletal disorders: Too much of a good thing. Trends Genet., 13, 178-182.
8. Bergsagel, P.L. and Kuehl, W.M. (2005) Molecular pathogenesis and a consequent classification of multiple myeloma. J. Clin. Oncol., 23, 6333-6338.
9. Chesi, M., Nardini, E., Brents, L.A., Schrock, E., Ried, T., Kuehl, W.M. and Bergsagel, P.L. (1997) Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat. Genet., 16, 260-264.
10. Richelda, R., Ronchetti, D., Baldini, L., Cro, L., Viggiano, L., Marzella, R., Rocchi, M., Otsuki, T., Lombardi, L., Maiolo, A.T. et al. (1997) A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood, 90, 4062-4070.
11. Moreau, P., Facon, T., Leleu, X., Morineau, N., Huyghe, P., Harousseau, J.L., Bataille, R. and Avet-Loiseau, H. (2002) Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood, 100, 1579-1583.
12. Intini, D., Baldini, L., Fabris, S., Lombardi, L., Ciceri, G., Maiolo, A.T. and Neri, A. (2001) Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). Br. J. Haematol., 114, 362-364.
13. Chen, J., Lee, B.H., Williams, I.R., Kutok, J.L., Mitsiades, C.S., Duclos, N., Cohen, S., Adelsperger, J., Okabe, R., Coburn, A. et al. (2005) FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene, 24, 8259-8267.
14. Trudel, S., Ely, S., Farooqi, Y., Affer, M., Robbiani, D.F., Chesi, M. and Bergsagel, P.L. (2004) Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood, 103, 3521-3528.
15. Trudel, S., Li, Z.H., Wei, E., Wiesmann, M., Chang, H., Chen, C., Reece, D., Heise, C. and Stewart, A.K. (2005) CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood, 105, 2941-2948.
16. Trudel, S., Stewart, A.K., Rom, E., Wei, E., Li, Z.H., Kotzer, S., Chumakov, I., Singer, Y., Chang, H., Liang, S.B. et al. (2006) The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood, 107, 4039-4046.
17. Xin, X., Abrams, T.J., Hollenbach, P.W., Rendahl, K.G., Tang, Y., Oei, Y.A., Embry, M.G., Swinarski, D.E., Garrett, E.N., Pryer, N.K. et al. (2006) CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice. Clin. Cancer Res., 12, 4908-4915.
18. Chen, J., Williams, I.R., Lee, B.H., Duclos, N., Huntly, B.J., Donoghue, D.J. and Gilliland, D.G. (2005) Constitutively activated FGFR3 mutants signal through PLCgamma-dependent and -independent pathways for hematopoietic transformation. Blood, 106, 328-337.
19. Chesi, M., Brents, L.A., Ely, S.A., Bais, C., Robbiani, D.F., Mesri, E.A., Kuehl, W.M. and Bergsagel, P.L. (2001) Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood, 97, 729-736.
20. Harvey, R.D. and Lonial, S. (2007) PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. Future Oncol., 3, 639-647.
21. Kang, S., Dong, S., Gu, T.L., Guo, A., Cohen, M.S., Lonial, S., Khoury, H.J., Fabbro, D., Gilliland, D.G., Bergsagel, P.L. et al. (2007) FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell, 12, 201-214.
22. Pollett, J.B., Trudel, S., Stern, D., Li, Z.H. and Stewart, A.K. (2002) Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance. Blood, 100 3819-3821.
23. Younes, H., Leleu, X., Hatjiharissi, E., Moreau, A.S., Hideshima, T., Richardson, P., Anderson, K.C. and Ghobrial, I.M. (2007) Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma. Clin. Cancer Res., 13, 3771-3775.
24. Murakami, S., Balmes, G., McKinney, S., Zhang, Z., Givol, D. and de Crombrugghe, B. (2004) Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype. Genes Dev., 18, 290-305.
25. Grand, E.K., Chase, A.J., Heath, C., Rahemtulla, A. and Cross, N.C. (2004) Targeting FGFR3 in multiple myeloma: Inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia, 18, 962-966.
26. Paterson, J.L., Li, Z., Wen, X.Y., Masih-Khan, E., Chang, H., Pollett, J.B., Trudel, S. and Stewart, A.K. (2004) Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma. Br. J. Haematol., 124, 595-603.
27. Zhao, L. and Vogt, P.K. (2008) Class I PI3K in oncogenic cellular transformation. Oncogene, 27, 5486-5496.
28. Piccione, E., Case, R.D., Domchek, S.M., Hu, P., Chaudhuri, M., Backer, J.M., Schlessinger, J. and Shoelson, S.E. (1993) Phosphatidylinositol 3-kinase p85 SH2 domain specificity defined by direct phosphopeptide/ SH2 domain binding. Biochemistry, 32, 3197-3202.
29. Holgado-Madruga, M., Emlet, D.R., Moscatello, D.K., Godwin, A.K. and Wong, A.J. (1996) A Grb2-associated docking protein in EGF- and insulin-receptor signalling. Nature, 379, 560-564.
30. Rodrigues, G.A., Falasca, M., Zhang, Z., Ong, S.H. and Schlessinger, J. (2000) A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling. Mol. Cell. Biol., 20, 1448-1459.
31. Yenush, L. and White, M.F. (1997) The IRS-signalling system during insulin and cytokine action. Bioessays, 19, 491-500.
32. Ong, S.H., Hadari, Y.R., Gotoh, N., Guy, G.R., Schlessinger, J. and Lax, I. (2001) Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins. Proc. Natl Acad. Sci. USA, 98, 6074-6079.
33. Garcia, Z., Kumar, A., Marques, M., Cortes, I. and Carrera, A.C. (2006) Phosphoinositide 3-kinase controls early and late events in mammalian cell division. EMBO J., 25, 655-661.
34. Song, G., Ouyang, G. and Bao, S. (2005) The activation of Akt/PKB signaling pathway and cell survival. J. Cell Mol. Med., 9, 59-71.
35. Vogt, P.K., Kang, S., Elsliger, M.A. and Gymnopoulos, M. (2007) Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem. Sci., 32, 342-349.
36. LoPiccolo, J., Granville, C.A., Gills, J.J. and Dennis, P.A. (2007) Targeting Akt in cancer therapy. Anticancer Drugs, 18, 861-874.
37. Min, Y.H., Cheong, J.W., Kim, J.Y., Eom, J.I., Lee, S.T., Hahn, J.S., Ko, Y.W. and Lee, M.H. (2004) Cytoplasmic mislocalization of p27Kip1 protein is associated with constitutive phosphorylation of Akt or protein kinase B and poor prognosis in acute myelogenous leukemia. Cancer Res., 64, 5225-5231.
38. Maeda, T., Yagasaki, F., Ishikawa, M., Takahashi, N. and Bessho, M. (2005) Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML. Blood, 105 2115-2123.
39. Menu, E., Kooijman, R., Van Valckenborgh, E., Asosingh, K., Bakkus, M., Van Camp, B. and Vanderkerken, K. (2004) Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: Study in the 5T33MM model. Br. J. Cancer, 90, 1076-1083.
40. Pene, F., Claessens, Y.E., Muller, O., Viguie, F., Mayeux, P., Dreyfus, F., Lacombe, C. and Bouscary, D. (2002) Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene, 21, 6587-6597.
41. Zhang, J., Choi, Y., Mavromatis, B., Lichtenstein, A. and Li, W. (2003) Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway. Oncogene, 22, 6289-6295.
42. Downward, J. (1997) Role of phosphoinositide-3-OH kinase in Ras signaling. Adv. Second Messenger Phosphoprotein Res., 31, 1-10.
43. Liu, L., Xie, Y. and Lou, L. (2006) PI3K is required for insulin-stimulated but not EGF-stimulated ERK1/2 activation. Eur. J. Cell Biol., 85, 367-374.
44. Sebolt-Leopold, J.S. and Herrera, R. (2004) Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer, 4, 937-947.
45. Vivanco, I. and Sawyers, C.L. (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer, 2, 489-501.
46. Wang, Q., Zhou, Y., Wang, X. and Evers, B.M. (2006) Glycogen synthase kinase-3 is a negative regulator of extracellular signal-regulated kinase. Oncogene, 25, 43-50.
47. Kong, M., Wang, C.S. and Donoghue, D.J. (2002) Interaction of fibroblast growth factor receptor 3 and the adapter protein SH2-B. A role in STAT5 activation. J. Biol. Chem., 277, 15962-15970.
48. Tavormina, P.L., Shiang, R., Thompson, L.M., Zhu, Y.Z., Wilkin, D.J., Lachman, R.S., Wilcox, W.R., Rimoin, D.L., Cohn, D.H. and Wasmuth, J.J. (1995) Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat. Genet., 9, 321-328.
49. Anderson, K.E. and Jackson, S.P. (2003) Class I phosphoinositide 3-kinases. Int. J. Biochem. Cell Biol., 35, 1028-1033.
50. Vanhaesebroeck, B., Ali, K., Bilancio, A., Geering, B. and Foukas, L.C. (2005) Signalling by PI3K isoforms: Insights from gene-targeted mice. Trends Biochem. Sci., 30, 194-204.
51. Otsu, M., Hiles, I., Gout, I., Fry, M.J., Ruiz-Larrea, F., Panayotou, G., Thompson, A., Dhand, R., Hsuan, J., Totty, N. et al. (1991) Characterization of two 85 kd proteins that associate with receptor tyrosine kinases, middle-T/pp60c-src complexes, and PI3-kinase. Cell 65, 91-104.
52. Pons, S., Asano, T., Glasheen, E., Miralpeix, M., Zhang, Y., Fisher, T.L., Myers, M.G. Jr, Sun, X.J. and White, M.F. (1995) The structure and function of p55PIK reveal a new regulatory subunit for phosphatidylinositol 3-kinase. Mol. Cell. Biol., 15, 4453-4465.
53. Raffioni, S., Zhu, Y.Z., Bradshaw, R.A. and Thompson, L.M. (1998) Effect of transmembrane and kinase domain mutations on fibroblast growth factor receptor 3 chimera signaling in PC12 cells. A model for the control of receptor tyrosine kinase activation. J. Biol. Chem., 273, 35250-35259.
54. Hu, Y., Fang, X., Dunham, S.M., Prada, C., Stachowiak, E.K. and Stachowiak, M.K. (2004) 90-kDa ribosomal S6 kinase is a direct target for the nuclear fibroblast growth factor receptor 1 (FGFR1): Role in FGFR1 signaling. J. Biol. Chem., 279, 29325-29335.
55. Ong, S.H., Guy, G.R., Hadari, Y.R., Laks, S., Gotoh, N., Schlessinger, J. and Lax, I. (2000) FRS2 proteins recruit intracellular signaling pathways by binding to diverse targets on fibroblast growth factor and nerve growth factor receptors. Mol. Cell. Biol., 20, 979-989.
56. Montagner, A., Yart, A., Dance, M., Perret, B., Salles, J.P. and Raynal, P. (2005) A novel role for Gab1 and SHP2 in epidermal growth factor-induced Ras activation. J. Biol. Chem., 280, 5350-5360.
57. Yart, A., Laffargue, M., Mayeux, P., Chretien, S., Peres, C., Tonks, N., Roche, S., Payrastre, B., Chap, H. and Raynal, P. (2001) A critical role for phosphoinositide 3-kinase upstream of Gab1 and SHP2 in the activation of ras and mitogen-activated protein kinases by epidermal growth factor. J. Biol. Chem., 276, 8856-8864.
58. Hart, K.C., Robertson, S.C. and Donoghue, D.J. (2001) Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation. Mol. Biol. Cell, 12 931-942.
59. Cross, M.J., Hodgkin, M.N., Roberts, S., Landgren, E., Wakelam, M.J. and Claesson-Welsh, L. (2000) Tyrosine 766 in the fibroblast growth factor receptor-1 is required for FGF-stimulation of phospholipase C, phospholipase D, phospholipase A(2), phosphoinositide 3-kinase and cytoskeletal reorganisation in porcine aortic endothelial cells. J. Cell Sci., 113, 643-651.
60. Mohammadi, M., Honegger, A.M., Rotin, D., Fischer, R., Bellot, F., Li, W., Dionne, C.A., Jaye, M., Rubinstein, M. and Schlessinger, J. (1991) A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1. Mol. Cell Biol., 11, 5068-5078.
61. Lievens, P.M., Roncador, A. and Liboi, E. (2006) K644E/M FGFR3 mutants activate Erk1/2 fromthe endoplasmic reticulum through FRS2 alpha and PLC gamma-independent pathways. J. Mol. Biol., 357, 783-792.
62. Hyun, T., Yam, A., Pece, S., Xie, X., Zhang, J., Miki, T., Gutkind, J.S. and Li, W. (2000) Loss of PTEN expression leading to high Akt activation in human multiple myelomas. Blood, 96, 3560-3568.
63. Thompson, L.M., Raffioni, S., Wasmuth, J.J. and Bradshaw, R.A. (1997) Chimeras of the native form or achondroplasia mutant (G375C) of human fibroblast growth factor receptor 3 induce ligand-dependent differentiation of PC12 cells. Mol. Cell. Biol., 17, 4169-4177.
64. Suenaga, A., Takada, N., Hatakeyama, M., Ichikawa, M., Yu, X., Tomii, K., Okimoto, N., Futatsugi, N., Narumi, T., Shirouzu, M. et al. (2005) Novel mechanism of interaction of p85 subunit of phosphatidylinositol 3-kinase and ErbB3 receptor-derived phosphotyrosyl peptides. J. Biol. Chem., 280, 1321-1326.
65. Ryan, P.J., Paterno, G.D. and Gillespie, L.L. (1998) Identification of phosphorylated proteins associated with the fibroblast growth factor receptor type I during early Xenopus development. Biochem. Biophys. Res. Commun., 244, 763-767.
66. Ishikawa, H., Tsuyama, N., Liu, S., Abroun, S., Li, F.J., Otsuyama, K., Zheng, X., Ma, Z., Maki, Y., Iqbal, M.S. et al. (2005) Accelerated proliferation of myeloma cells by interleukin-6 cooperating with fibroblast growth factor receptor 3-mediated signals. Oncogene, 24, 6328-6332.
67. Krejci, P., Mekikian, P.B. and Wilcox, W.R. (2006) The fibroblast growth factors in multiple myeloma. Leukemia, 20, 1165-1168.
68. Munugalavadla, V., Sims, E.C., Borneo, J., Chan, R.J. and Kapur, R. (2007) Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis. Blood, 110, 1612-1620.
69. Guan, K.L., Figueroa, C., Brtva, T.R., Zhu, T., Taylor, J., Barber, T.D. and Vojtek, A.B. (2000) Negative regulation of the serine/threonine kinase B-Raf by Akt. J. Biol. Chem., 275, 27354-27359.
70. Moelling, K., Schad, K., Bosse, M., Zimmermann, S. and Schweneker, M. (2002) Regulation of Raf-Akt Cross-talk. Biol. Chem., 277, 31099-31106.
71. Rommel, C., Clarke, B.A., Zimmermann, S., Nunez, L., Rossman, R., Reid, K., Moelling, K., Yancopoulos, G.D. and Glass, D.J. (1999) Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science, 286, 1738-1741.
72. Priore, R., Dailey, L. and Basilico, C. (2006) Downregulation of Akt activity contributes to the growth arrest induced by FGF in chondrocytes. J. Cell Physiol., 207, 800-808.
73. Hanafusa, H., Torii, S., Yasunaga, T. and Nishida, E. (2002) Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway. Nat. Cell Biol., 4, 850-858.
74. McKay, M.M. and Morrison, D.K. (2007) Integrating signals from RTKs to ERK/MAPK. Oncogene, 26, 3113-3121.
75. Seiden-Long, I., Navab, R., Shih, W., Li, M., Chow, J., Zhu, C.Q., Radulovich, N., Saucier, C. and Tsao, M.S. (2008) Gab1 but not Grb2 mediates tumor progression in Met overexpressing colorectal cancer cells. Carcinogenesis, 29, 647-655.
76. Koyama, T., Nakaoka, Y., Fujio, Y., Hirota, H., Nishida, K., Sugiyama, S., Okamoto, K., Yamauchi-Takihara, K., Yoshimura, M., Mochizuki, S. et al. (2008) Interaction of scaffolding adaptor protein Gab1 with tyrosine phosphatase SHP2 negatively regulates IGF-I-dependent myogenic differentiation via the ERK1/2 signaling pathway. J. Biol. Chem., 283, 24234-24244.
77. Hall, H., Williams, E.J., Moore, S.E., Walsh, F.S., Prochiantz, A. and Doherty, P. (1996) Inhibition of FGF-stimulated phosphatidylinositol hydrolysis and neurite outgrowth by a cell-membrane permeable phosphopeptide. Curr. Biol., 6, 580-587.
78. Krejci, P., Masri, B., Salazar, L., Farrington-Rock, C., Prats, H., Thompson, L.M. and Wilcox, W.R. (2007) Bisindolylmaleimide I suppresses fibroblast growth factor-mediated activation of Erk MAP kinase in chondrocytes by preventing Shp2 association with the Frs2 and Gab1 adaptor proteins. J. Biol. Chem., 282, 2929-2936.
79. Vojtek, A.B., Hollenberg, S.M. and Cooper, J.A. (1993) Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell, 74, 205-214.
80. Lefai, E., Roques, M., Vega, N., Laville, M. and Vidal, H. (2001) Expression of the splice variants of the p85alpha regulatory subunit of phosphoinositide 3-kinase in muscle and adipose tissue of healthy subjects and type 2 diabetic patients. Biochem. J., 360, 117-126.
81. Bonofiglio, D., Gabriele, S., Aquila, S., Catalano, S., Gentile, M., Middea, E., Giordano, F. and Ando, S. (2005) Estrogen receptor alpha binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor gamma signaling in breast cancer cells. Clin. Cancer Res., 11 6139-6147.